Multiple Sclerosis

Neurology·MeSH: Multiple Sclerosis, Relapsing-Remitting

Prevalence

120.0 / 100K

Incidence

7.0 / 100K/yr

159 drugs in development·60 companies·73 clinical trials

Drug Pipeline by Phase

Approved(24)

Drug	Company
ampyra	Acorda Therapeutics, Inc. (ACOR)
baclofen	ANI PHARMACEUTICALS INC (ANIP)
baclofen	Impax Laboratories, LLC (IPXL)
BRIUMVI	TG THERAPEUTICS, INC. (TGTX)
Cortrophin Gel	ANI PHARMACEUTICALS INC (ANIP)
dimethyl	Mylan II B.V. (MYL)
fampyra	Acorda Therapeutics, Inc. (ACOR)
fingolimod	SUNSET ISLAND GROUP (SUN)
fingolimod	DR REDDYS LABORATORIES LTD (RDY)
fingolimod	Mylan II B.V. (MYL)
fingolimod	GT Biopharma, Inc. (GTBP)
fingolimod	Teva Pharmaceutical Industries Limited (TEVA)
fingolimod	ICON plc (ICLR)
fingolimod	Aptinyx Inc. (APTX)
fingolimod	aTYR PHARMA INC (ATYR)
plegridy	BIOGEN INC. (BIIB)
ponvory	Vanda Pharmaceuticals Inc. (VNDA)
Purified Cortrophin Gel	ANI PHARMACEUTICALS INC (ANIP)
tascenso odt	BICYCLE THERAPEUTICS PLC (BCYC)
teriflunomide	Mersana Therapeutics, Inc. (MRSN)
teriflunomide	Aptinyx Inc. (APTX)
triamcinolone acetonide	Teva Pharmaceutical Industries Limited (TEVA)
Tysabri	Royalty Pharma plc (RPRX)
VUMERITY	Alkermes plc. (ALKS)

Phase 3(68)

Drug	Company
13-valent pneumococcal conjugate vaccine	Novartis AG (NVS)
13-valent pneumococcal conjugate vaccine	NOVARTIS AG (NVSEF)
23-valent pneumococcal polysaccharide vaccine	Novartis AG (NVS)
23-valent pneumococcal polysaccharide vaccine	NOVARTIS AG (NVSEF)
abp 692	AMGEN INC (AMGN)
activated charcoal	Sanofi (SNY)
activated charcoal	Sanofi (SNYNF)
ads-5102	Adamas Pharmaceuticals Inc (ADMS)
alemtuzumab gz402673	Sanofi (SNY)
ANAVEX®2-73	ANAVEX LIFE SCIENCES CORP. (AVXL)
Apitox (Apitoxin in South Korea)	Apimeds Pharmaceuticals US, Inc. (APUS)
arbaclofen	RVL Pharmaceuticals plc (RVLP)
arbaclofen er	RVL Pharmaceuticals plc (RVLP)
azd0120 - regimen 1	ASTRAZENECA PLC (AZN)
azd0120 - regimen 2	ASTRAZENECA PLC (AZN)
beta-interferon	Sanofi (SNY)
ceterizine	Sanofi (SNY)
dexchlorpheniramine	Sanofi (SNY)
dimethyl	BIOGEN INC. (BIIB)
diphenydramine	Sanofi (SNY)
diroximel	BIOGEN INC. (BIIB)
fingolimod	BRISTOL MYERS SQUIBB CO (BMY)
fingolimod	BIOGEN INC. (BIIB)
Fingolimod	Novartis AG (NVS)
first line dmt	Novartis AG (NVS)
first line dmt	NOVARTIS AG (NVSEF)
frexalimab	Sanofi (SNY)
Frexalimab	Sanofi (SNY)
glatiramer	Sanofi (SNY)
imu-838	IMMUNIC, INC. (IMUX)
interferon beta	BIOGEN INC. (BIIB)
interferon beta-1a	Novartis AG (NVS)
interferon β-1a	BIOGEN INC. (BIIB)
Intra-detrusor injection of Onabotulinumtoxin-A	Revance Therapeutics, Inc. (RVNC)
keyhole limpet hemocyanin neo-antigen	Novartis AG (NVS)
keyhole limpet hemocyanin neo-antigen	NOVARTIS AG (NVSEF)
mri contrast-enhancing agents	Sanofi (SNY)
mri contrast-enhancing preparations	Sanofi (SNYNF)
mRNA-1195	Moderna, Inc. (MRNA)
nabiximols	GW PHARMACEUTICALS PLC (GWPH)
obexelimab	Zenas BioPharma, Inc. (ZBIO)
ocrelizumab	AMGEN INC (AMGN)
ocrelizumab	Novartis AG (NVS)
Ocrelizumab	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ofatumumab	Novartis AG (NVS)
ofatumumab approved dose	Novartis AG (NVS)
Ofatumumab approved dose	Novartis AG (NVS)
ofatumumab new dose	Novartis AG (NVS)
Ofatumumab new dose	Novartis AG (NVS)
orelabrutinib	Zenas BioPharma, Inc. (ZBIO)
other h1 antagonist	Sanofi (SNY)
ozanimod	BRISTOL MYERS SQUIBB CO (BMY)
ozanimod	CELGENE CORP /DE/ (CELG)
paracetamol	Sanofi (SNY)
ranitidine	Sanofi (SNY)
Remibrutinib	Novartis AG (NVS)
remibrutinib oral treatment	Novartis AG (NVS)
Remibrutinib oral treatment	Novartis AG (NVS)
seasonal quadrivalent influenza vaccine	Novartis AG (NVS)
seasonal quadrivalent influenza vaccine	NOVARTIS AG (NVSEF)
Siponimod	Novartis AG (NVS)
teriflunomide hmr1726	Sanofi (SNY)
tetanus toxoid containing vaccine (td	Novartis AG (NVS)
tetanus toxoid containing vaccine (td	NOVARTIS AG (NVSEF)
Ublituximab	TG THERAPEUTICS, INC. (TGTX)
Ublituximab IV Simplified Dosing Schedule	TG THERAPEUTICS, INC. (TGTX)
Ublituximab Subcutaneous	TG THERAPEUTICS, INC. (TGTX)
vidofludimus	IMMUNIC, INC. (IMUX)

Phase 2(23)

Drug	Company
biib091	BIOGEN INC. (BIIB)
CC-97540	BRISTOL MYERS SQUIBB CO (BMY)
cenplacel-l	Celularity Inc. (CELU)
Cladribine	UNITED THERAPEUTICS Corp (UTHR)
cnm-au8	Clene Inc. (CLNN)
drf	BIOGEN INC. (BIIB)
foralumab	Tiziana Life Sciences Ltd (TLSA)
foralumab tzls-401	Tiziana Life Sciences Ltd (TLSA)
gold nanocrystals	Clene Inc. (CLNN)
hp 13c pyruvate	Bio Green Med Solution, Inc. (BGMSP)
Ketamine	UNITED THERAPEUTICS Corp (UTHR)
ly3541860	ELI LILLY & Co (LLY)
mb-cart2019.1	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
Midazolam	UNITED THERAPEUTICS Corp (UTHR)
mri contrast-enhancing preparations	Sanofi (SNY)
N-acetyl cysteine	UNITED THERAPEUTICS Corp (UTHR)
obe-cel	Autolus Therapeutics plc (AUTL)
obecabtagene autoleucel	Autolus Therapeutics plc (AUTL)
sar441344 iv	Sanofi (SNY)
sar441344 sc	Sanofi (SNY)
sar442168	Sanofi (SNY)
sar443820	Sanofi (SNY)
Tolebrutinib	Sanofi (SNY)

Phase 1(8)

Drug	Company
antihistamine	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
bryostatin-1	TAO Synergies Inc. (TAOX)
KYV-101 anti-CD19 CAR-T cell therapy	FATE THERAPEUTICS INC (FATE)
LP659	Longboard Pharmaceuticals, Inc. (LBPH)
prn2246/sar442168	Principia Biopharma Inc. (PRNB)
rese-cel (resecabtagene autoleucel)	Cabaletta Bio, Inc. (CABA)
rifampicin	Sanofi (SNY)
Standard lymphodepletion regimen	FATE THERAPEUTICS INC (FATE)

Preclinical(13)

Drug	Company
apitox	Apimeds Pharmaceuticals US, Inc. (APUS)
ergod2 neuro	ENTIA BIOSCIENCES, INC. (ERGO)
feldetrex	PREMIER BIOMEDICAL INC (BIEI)
labp-66	Landos Biopharma, Inc. (LABP)
ms treatment	GLOBESTAR THERAPEUTICS CORP (SOAN)
nexi-004	NexImmune, Inc. (NEXI)
patented formulation of previously approved drugs	GLOBESTAR THERAPEUTICS CORP (SOAN)
project amethyst	GLOBESTAR THERAPEUTICS CORP (SOAN)
rpi-78m	NUTRA PHARMA CORP (NPHC)
sequential-dialysis technique	PREMIER BIOMEDICAL INC (BIEI)
SPU-16	Silo Pharma, Inc. (SILO)
stat-203	Statera Biopharma, Inc. (CBLI)
unspecified	Tevogen Bio Holdings Inc. (TVGN)

Unknown(13)

Drug	Company
alemtuzumab	Sanofi (SNYNF)
alemtuzumab	Sanofi (SNY)
alemtuzumab	BIOGEN INC. (BIIB)
glatiramer	BIOGEN INC. (BIIB)
Mavenclad	Merck & Co., Inc. (MRK)
natalizumab	BIOGEN INC. (BIIB)
Novel MS therapeutic target (discovery)	Adaptive Biotechnologies Corp (ADPT)
ocrelizumab	BIOGEN INC. (BIIB)
ofatumumab	BIOGEN INC. (BIIB)
ozanimod	BIOGEN INC. (BIIB)
peginterferon beta-1a	BIOGEN INC. (BIIB)
siponimod	BIOGEN INC. (BIIB)
u.s. patent 10	GLOBESTAR THERAPEUTICS CORP (SOAN)

Phase 2/Phase 3(2)

Drug	Company
CABA-201	Cabaletta Bio, Inc. (CABA)
Fingolimod	TG THERAPEUTICS, INC. (TGTX)

Phase 4(8)

Drug	Company
disease modifying treatment	Novartis AG (NVS)
disease modifying treatment	NOVARTIS AG (NVSEF)
fingolimod	Novartis AG (NVS)
Ocrelizumab	Novartis AG (NVS)
Ofatumumab	Novartis AG (NVS)
ofatunumab	Novartis AG (NVS)
ofatunumab	Novartis AG (NVS)
Teriflunomide	Sanofi (SNY)

Compare drugs

ampyra vs baclofen ampyra vs BRIUMVI ampyra vs Cortrophin Gel

Frequently asked questions

How many drugs are in development for Multiple Sclerosis?

BioSniper tracks 159 drugs in development for Multiple Sclerosis across 60 companies.

How many clinical trials target Multiple Sclerosis?

There are 73 clinical trials targeting Multiple Sclerosis tracked by BioSniper.

What is the prevalence of Multiple Sclerosis?

The estimated prevalence of Multiple Sclerosis is approximately 120.0 per 100,000 population.

Deep-dive into Multiple Sclerosis

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis